178 related articles for article (PubMed ID: 12019198)
1. Inhibition kinetics of monoclonal antibodies against cytochromes P450.
Mei Q; Tang C; Lin Y; Rushmore TH; Shou M
Drug Metab Dispos; 2002 Jun; 30(6):701-8. PubMed ID: 12019198
[TBL] [Abstract][Full Text] [Related]
2. A monoclonal antibody inhibitory to human P450 2D6: a paradigm for use in combinatorial determination of individual P450 role in specific drug tissue metabolism.
Gelboin HV; Krausz KW; Shou M; Gonzalez FJ; Yang TJ
Pharmacogenetics; 1997 Dec; 7(6):469-77. PubMed ID: 9429232
[TBL] [Abstract][Full Text] [Related]
3. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
4. Role of a potent inhibitory monoclonal antibody to cytochrome P-450 3A4 in assessment of human drug metabolism.
Mei Q; Tang C; Assang C; Lin Y; Slaughter D; Rodrigues AD; Baillie TA; Rushmore TH; Shou M
J Pharmacol Exp Ther; 1999 Nov; 291(2):749-59. PubMed ID: 10525096
[TBL] [Abstract][Full Text] [Related]
5. Identification of metabolic pathways involved in the biotransformation of tolperisone by human microsomal enzymes.
Dalmadi B; Leibinger J; Szeberényi S; Borbás T; Farkas S; Szombathelyi Z; Tihanyi K
Drug Metab Dispos; 2003 May; 31(5):631-6. PubMed ID: 12695352
[TBL] [Abstract][Full Text] [Related]
6. Use of inhibitory monoclonal antibodies to assess the contribution of cytochromes P450 to human drug metabolism.
Shou M; Lu T; Krausz KW; Sai Y; Yang T; Korzekwa KR; Gonzalez FJ; Gelboin HV
Eur J Pharmacol; 2000 Apr; 394(2-3):199-209. PubMed ID: 10771285
[TBL] [Abstract][Full Text] [Related]
7. Characterization of six in vitro reactions mediated by human cytochrome P450: application to the testing of cytochrome P450-directed antibodies.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Duan SX; Karsov D; Shader RI
Pharmacology; 1996 Feb; 52(2):125-34. PubMed ID: 8851634
[TBL] [Abstract][Full Text] [Related]
8. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
9. Differential roles of cytochromes P450 2D1, 2C11, and 1A1/2 in the hydroxylation of bufuralol by rat liver microsomes.
Mimura M; Yamazaki H; Sugahara C; Hiroi T; Funae Y; Shimada T
Biochem Pharmacol; 1994 Jun; 47(11):1957-63. PubMed ID: 7912070
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory monoclonal antibodies to human cytochrome P450 2D6.
Krausz KW; Yang TJ; Gonzalez FJ; Shou M; Gelboin HV
Biochem Pharmacol; 1997 Jul; 54(1):15-7. PubMed ID: 9296346
[TBL] [Abstract][Full Text] [Related]
11. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
Uttamsingh V; Lu C; Miwa G; Gan LS
Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies specific and inhibitory to human cytochromes P450 2C8, 2C9, and 2C19.
Krausz KW; Goldfarb I; Buters JT; Yang TJ; Gonzalez FJ; Gelboin HV
Drug Metab Dispos; 2001 Nov; 29(11):1410-23. PubMed ID: 11602516
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory monoclonal antibodies to human cytochrome P450 1A2: analysis of phenacetin O-deethylation in human liver.
Yang TJ; Sai Y; Krausz KW; Gonzalez FJ; Gelboin HV
Pharmacogenetics; 1998 Oct; 8(5):375-82. PubMed ID: 9825829
[TBL] [Abstract][Full Text] [Related]
14. Expression, purification, and characterization of mouse CYP2d22.
Yu AM; Haining RL
Drug Metab Dispos; 2006 Jul; 34(7):1167-74. PubMed ID: 16595712
[TBL] [Abstract][Full Text] [Related]
15. Characterization of human cytochrome P450 isoenzymes involved in the metabolism of vinorelbine.
Beulz-Riché D; Grudé P; Puozzo C; Sautel F; Filaquier C; Riché C; Ratanasavanh D
Fundam Clin Pharmacol; 2005 Oct; 19(5):545-53. PubMed ID: 16176333
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
Davis JA; Rock DA; Wienkers LC; Pearson JT
Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
[TBL] [Abstract][Full Text] [Related]
17. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes.
Nakamura K; Yokoi T; Inoue K; Shimada N; Ohashi N; Kume T; Kamataki T
Pharmacogenetics; 1996 Oct; 6(5):449-57. PubMed ID: 8946477
[TBL] [Abstract][Full Text] [Related]
18. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
19. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
20. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CTP2D6 and CYP3A activities?
Yu A; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1514-20. PubMed ID: 11602530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
